Creo
Medical Group plc
("Creo"
the "Company" or the "Group")
Award of Shares under Share Incentive Plan,
Director Dealings, Issue of Equity and TVR
Creo Medical Group plc (AIM: CREO), the medical
device company focused on the emerging field of surgical
endoscopy, implemented an HMRC approved Share Incentive Plan
("SIP") during 2020 which is available to all of the Company's UK
based employees, including Directors.
Under the SIP, shares are acquired in four ways:
·
Partnership Shares where an employee can spend up to a £1,800 or
10% of their pre-tax income, whichever is the lower;
· Matching
Shares, where Creo can give up to two free Matching Shares for each
Partnership Share bought. The plan requires employees to
remain in employment for three years to benefit from the Matching
Shares;
· Free
Shares, where Creo can give up to £3,600 of free shares in any tax
year; and
· Dividend
Shares where additional shares can be bought with any dividends
paid.
The Company has been notified that Fiduchi Trustees
(UK) Limited ("Fiduchi"), the independent trustee of the SIP,
acquired, in accordance with the SIP's rules and on behalf of SIP
participants, 227,084 ordinary shares in the Company ("Ordinary
Shares"), at a price of £0.3275 per Ordinary Share on 16 July 2024
to meet its obligations under the SIP. Under the terms of the
SIP, the Company is required to issue to the SIP, two Ordinary
Shares in the Company for each Partnership Share purchased (being
454,168 Ordinary Shares in total). Fiduchi holds 150,740
unallocated shares within the SIP (being shares previously
allocated to employees who ceased employment before the shares had
vested) which can be utilised to part satisfy the Company's
obligation. Accordingly, 303,428 new Ordinary Shares are required
to be issued by the Company to be held by Fiduchi as trustee of the
SIP.
Craig Gulliford, Richard Rees and Christopher
Hancock, executive directors of the Company (the "Participating
Directors") have received Partnership Shares at a price of £0.3275
per share and Matching Shares at a price of £0.001 per share in
accordance with terms of the SIP (the "Transaction"). Following
this the Participating Directors' shareholdings in the Company are
as set out in the table below:
|
Director
|
Total number of
Ordinary Shares purchased or awarded under SIP
|
Total number of
Ordinary Shares held post Transaction
|
|
Craig Gulliford, CEO
|
8,244
|
1,652,771[1]
|
|
Richard Rees, CFO
|
8,244
|
2,828,207
|
|
Christopher Hancock, CTO
|
8,244
|
4,824,657
|
[1] This
figure includes 1,000,000 shares held by Mr Gulliford’s
wife.
Accordingly, the Company announces that it has made
an application for 303,428 new Ordinary Shares to be admitted to
trading on AIM. It is expected that admission will take place
on 6 August 2024. Following the allotment and issue, the
Company's issued share capital consists of 361,779,870 Ordinary
Shares. The Company does not hold any shares in Treasury. As
such the total number of shares in issue with voting rights is
361,779,870.
Total Voting Rights
(TVR)
The above figure of 361,779,870 may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure Guidance and Transparency Rules.
The notifications below, made in accordance with the
requirements of the Market Abuse Regulation, provide further detail
in relation to the award of the SIP Shares to the Participating
Directors.
Enquiries:
|
Creo Medical Group
plc
|
www.creomedical.com
|
|
Richard Rees (CFO)
Richard Craven (Company Secretary)
|
+44 (0)1291 606 005
|
|
|
|
|
Cavendish Capital
Markets Limited
|
+44 (0)20 7220 0500
|
|
Stephen Keys / Camilla Hume (NOMAD)
|
|
|
Michael Johnson (Sales)
|
|
|
|
|
|
Deutsche Numis
(Joint Broker)
Freddie Barnfield / Duncan Monteith / Euan Brown
|
+44 (0)20
7260 1000
|
|
|
|
|
Walbrook PR
Ltd
|
Tel: +44 (0)20 7933 8780 or
creo@walbrookpr.com
|
|
Paul McManus / Sam
Allen /
Phillip Marriage
|
Mob: +44
(0)7980 541 893 / +44 (0)7502 558 258 / +44
(0)7867 984 082
|
About Creo
Medical
Creo is a medical device company focused on the
development and commercialisation of minimally invasive
electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes
through the development and commercialisation of a suite of
electrosurgical medical devices, each enabled by CROMA, powered by
Kamaptive. The Group has developed the CROMA powered by Kamaptive
full-spectrum adaptive technology to optimise surgical capability
and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically
adapt to patient tissue during procedures such as resection,
dissection, coagulation, and ablation of tissue. Kamaptive
technology provides clinicians with increased flexibility,
precision and controlled surgical solutions. CROMA currently
delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for
controlled coagulation and ablation via a single accessory port.
This technology, combined with the Group's range of patented
electrosurgical devices, is designed to provide clinicians with
flexible, accurate and controlled clinical solutions. The Directors
believe the Company's technology can impact the landscape of
surgery and endoscopy by providing a safer, less invasive and more
cost-efficient option for procedures.
For more information, please refer to the website
www.creomedical.com
|
1.
Details of PDMR
|
|
a)
|
Name
|
Craig Gulliford
|
|
b)
|
Position / status
|
CEO
|
|
c)
|
Initial notification / amendment
|
Initial notification
|
|
2. Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary Shares
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares under Share Incentive
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Prices
|
Volume(s)
|
|
£0.3275
|
2,748
|
|
|
d)
|
Aggregated information
Aggregated volume Price
|
N/A - Single transaction
|
|
e)
|
Date of the
transaction
|
2024-07-16 GMT
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|
|
1.
Details of PDMR
|
|
a)
|
Name
|
Craig Gulliford
|
|
b)
|
Position / status
|
CEO
|
|
c)
|
Initial notification / amendment
|
Initial notification
|
|
2. Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary Shares
|
|
b)
|
Nature of the transaction
|
Award of Ordinary Shares under Share Incentive
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Prices
|
Volume(s)
|
|
£0.001
|
5,496
|
|
|
d)
|
Aggregated information
Aggregated volume Price
|
N/A - Single transaction
|
|
e)
|
Date of the
transaction
|
2024-07-31 GMT
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|
|
1.
Details of PDMR
|
|
a)
|
Name
|
Richard Rees
|
|
b)
|
Position / status
|
CFO
|
|
c)
|
Initial notification / amendment
|
Initial notification
|
|
2. Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary Shares
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares under Share Incentive
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Prices
|
Volume(s)
|
|
£0.3275
|
2,748
|
|
|
d)
|
Aggregated information
Aggregated volume Price
|
N/A - Single transaction
|
|
e)
|
Date of the
transaction
|
2024-07-16 GMT
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|
|
1.
Details of PDMR
|
|
a)
|
Name
|
Richard Rees
|
|
b)
|
Position / status
|
CFO
|
|
c)
|
Initial notification / amendment
|
Initial notification
|
|
2. Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary Shares
|
|
b)
|
Nature of the transaction
|
Award of Ordinary Shares under Share Incentive
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Prices
|
Volume(s)
|
|
£0.001
|
5,496
|
|
|
d)
|
Aggregated information
Aggregated volume Price
|
N/A - Single transaction
|
|
e)
|
Date of the
transaction
|
2024-07-31 GMT
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|
|
1.
Details of PDMR
|
|
a)
|
Name
|
Christopher Hancock
|
|
b)
|
Position / status
|
CTO
|
|
c)
|
Initial notification / amendment
|
Initial notification
|
|
2. Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary Shares
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares under Share Incentive
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Prices
|
Volume(s)
|
|
£0.3275
|
2,748
|
|
|
d)
|
Aggregated information
Aggregated volume Price
|
N/A - Single transaction
|
|
e)
|
Date of the
transaction
|
2024-07-16 GMT
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|
|
1.
Details of PDMR
|
|
a)
|
Name
|
Christopher Hancock
|
|
b)
|
Position / status
|
CTO
|
|
c)
|
Initial notification / amendment
|
Initial notification
|
|
2. Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been conducted
|
|
a)
|
Description of the financial instrument
|
Ordinary Shares
|
|
b)
|
Nature of the transaction
|
Award of Ordinary Shares under Share Incentive
Plan
|
|
c)
|
Price(s) and volume(s)
|
|
Prices
|
Volume(s)
|
|
£0.001
|
5,496
|
|
|
d)
|
Aggregated information
Aggregated volume Price
|
N/A - Single transaction
|
|
e)
|
Date of the
transaction
|
2024-07-31 GMT
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|